Key result
High-throughput sequencing established a definite genetic diagnosis in 59.8% of Chilean patients with limb-girdle muscle weakness, most frequently involving DYSF and CAPN3 genes.
Why the study?
In Chile, specific registries describing the distinct forms of hereditary myopathies are lacking.
What is the diagnostic yield and genetic profile of high-throughput sequencing in Chilean patients with limb-girdle muscle weakness?
Observational (n=82)
What is the diagnostic yield and genetic profile of high-throughput sequencing in Chilean patients with limb-girdle muscle weakness?
High-throughput sequencing provides a definite or highly probable genetic diagnosis in nearly 70% of Chilean patients with limb-girdle muscle weakness, highlighting a relatively high incidence of dysferlinopathy.
Supports high-throughput sequencing for limb-girdle weakness diagnosis in Chileans; leaves open validation across other ancestries.
Hereditary myopathies are a group of genetically determined muscle disorders comprising more than 300 entities. In Chile, there are no specific registries of the distinct forms of these myopathies. We now report the genetic findings of a series of Chilean patients presenting with limb-girdle muscle weakness of unknown etiology. Eighty-two patients were explored using high-throughput sequencing approaches with neuromuscular gene panels, establishing a definite genetic diagnosis in 49 patients (59.8%) and a highly probable genetic diagnosis in eight additional cases (9.8%). The most frequent causative genes identified were DYSF and CAPN3, accounting for 22% and 8.5% of the cases, respectively, followed by DMD (4.9%) and RYR1 (4.9%). The remaining 17 causative genes were present in one or two cases only. Twelve novel variants were identified. Five patients (6.1%) carried a variant of uncertain significance in genes partially matching the clinical phenotype. Twenty patients (24.4%) did not carry a pathogenic or likely pathogenic variant in the phenotypically related genes, including five patients (6.1%) presenting an autoimmune neuromuscular disorder. The relative frequency of the different forms of myopathy in Chile is like that of other series reported from different regions of the world with perhaps a relatively higher incidence of dysferlinopathy.
No takes yet. Share an insight, caveat, or question.
Cérino et al. (2022) conducted an observational in Limb-girdle muscle weakness of unknown etiology (n=82). High-throughput sequencing with neuromuscular gene panels was evaluated on Definite genetic diagnosis. High-throughput sequencing established a definite genetic diagnosis in 59.8% of Chilean patients with limb-girdle muscle weakness, most frequently involving DYSF and CAPN3 genes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: